Cost Effectiveness and Budget Impact of Nivolumab Plus Ipilimumab Versus Platinum Plus Pemetrexed (with and Without Bevacizumab) in Patients with Unresectable Malignant Pleural Mesothelioma in Switzerland

BACKGROUND: Malignant pleural mesotheliomas (MPMs) are aggressive and often unresectable. In the past, chemotherapy was the standard for palliative treatment. However, immunotherapy with nivolumab+ipilimumab has recently received marketing approval. OBJECTIVES: This study evaluated the cost effectiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Barbier, Michaela Carla, Fengler, Alicia, Pardo, Esther, Bhadhuri, Arjun, Meier, Niklaus, Gautschi, Oliver
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10635986/
https://www.ncbi.nlm.nih.gov/pubmed/37572261
http://dx.doi.org/10.1007/s40273-023-01305-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10635986/
https://www.ncbi.nlm.nih.gov/pubmed/37572261
http://dx.doi.org/10.1007/s40273-023-01305-3

Ejemplares similares